Evidence map›Paper›PMID 42156534›Full record

ArticleNature biotechnology2026

Zero-shot de novo peptide sequencing with open posttranslational modification discovery.

Zeping Mao, Chao Peng, Yuling Chen, Ping Wu, Qianqiu Zhang, Yonghan Yu, Ruixue Zhang, Lei Xin, Baozhen Shan, Haiteng Deng and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zeping MaoDavid R. Cheriton School of Computer Science, University of Waterloo, Waterloo, Ontario, Canada.ORCID http://orcid.org/0000-0003-1194-9118
Chao Peng *Baizhen Biotechnologies, Wuhan, China.
Yuling Chen *School of Life Science, Tsinghua University, Beijing, China.
Ping Wu *Baizhen Biotechnologies, Wuhan, China.
Qianqiu Zhang *David R. Cheriton School of Computer Science, University of Waterloo, Waterloo, Ontario, Canada.
Yonghan Yu *David R. Cheriton School of Computer Science, University of Waterloo, Waterloo, Ontario, Canada.
Ruixue Zhang *David R. Cheriton School of Computer Science, University of Waterloo, Waterloo, Ontario, Canada.
Lei XinBioinformatics Solutions, Waterloo, Ontario, Canada.ORCID http://orcid.org/0000-0003-1619-1545
Baozhen ShanBioinformatics Solutions, Waterloo, Ontario, Canada.ORCID http://orcid.org/0000-0002-8757-5493
Haiteng DengSchool of Life Science, Tsinghua University, Beijing, China. dht@mail.tsinghua.edu.cn.ORCID http://orcid.org/0000-0001-9496-1280
Ming LiDavid R. Cheriton School of Computer Science, University of Waterloo, Waterloo, Ontario, Canada. mli@uwaterloo.ca.ORCID http://orcid.org/0000-0002-2157-2775

Funding

Canadian Network for Research and Innovation in Machining Technology, Natural Sciences and Engineering Research Council of Canada (NSERC Canadian Network for Research and Innovation in Machining Technology) OGP0046506
6 · The paper itself

Abstract

De novo peptide sequencing directly infers sequences from mass spectrometry data without relying on protein databases. Although recent deep learning models can also identify posttranslational modifications (PTMs), they require labeled training data for this task. Here we introduce rotary positional embedding-enhanced de novo sequencing algorithm (RNovA), a transformer-based de novo sequencing algorithm enhanced with relative positional embeddings and a reinforcement-learning-style sequential decision framework. RNovA enables open PTM discovery in a zero-shot setting-without retraining or a predefined list of candidate residues-while maintaining state-of-the-art performance on standard benchmarks. Demonstrating this capability, we successfully identified peptides modified by kynurenine-an uncommon and biologically relevant PTM-in clinical samples from patients with RA and validated this discovery with synthetically synthesized reference peptides. Furthermore, we demonstrated open de novo PTM discovery by analyzing the bacterial strain A1232E, which lacks a reference proteome, and detected an unannotated glutamic acid modification. RNovA enables exploration of previously inaccessible regions of the proteome, including peptides with unexpected or unannotated modifications.

Identifiers

PMID42156534

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.